FOR PLAQUE PSORIASIS
ZORYVE® IT
RELIEVE IT
ANYWHERE
ZORYVE treats it, wherever patients need it,
with an easy, once-daily, steroid-free topical1
Symptoms illustrated. Not an actual patient.
ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use.1
ZORYVE treats it, wherever patients need it, with an easy, once-daily, steroid-free topical1
ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use.1
Simplify plaque psoriasis clearance with ZORYVE (zor-EEV)
40% of patients achieved IGA Success at Week 8, some as early as Week 41,2
RAPID, RELIABLE RESULTS ANYWHERE1,3,4
SEE EFFICACY DATACONSISTENTLY WELL TOLERATED AND SAFE1,5
VIEW SAFETY DATAPATIENT-FRIENDLY CREAM FORMULATION FOR EASY, LONG-TERM DISEASE CONTROL1,6
DISCOVER THE UNIQUE FORMULATIONIGA Success = Achievement of Clear (0)/Almost Clear (1) and a ≥2-grade improvement from baseline. IGA = Investigator Global Assessment.
Actor portrayal
A 2021 survey of >500 plaque psoriasis patients showed 9 OUT OF 10 TOPICAL USERS (89%) are interested in trying a new topical7*
*This survey was conducted online by The Harris Poll on behalf of Arcutis Biotherapeutics among US adults 18+ who have been diagnosed with psoriasis by a healthcare provider. The survey was conducted in 2021, among 507 plaque psoriasis patients. Figures were weighted where necessary to bring the data into line with actual proportions in the population using a multistep weighting process.
One ZORYVE Direct Savings Program helps eligible, commercially insured patients get access and start ZORYVE treatment quickly and easily†‡
Patient Access Support
Savings Program
Adherence Support
†Prescriptions will be delivered to the patient 1–2 days after processing.
‡Subject to eligibility criteria and maximum program limitation. This offer is not valid for patients without commercial drug insurance or whose prescription claims are eligible to be reimbursed, in whole or in part, by any government program. Please see Terms and Conditions.